Several next-generation nucleoside and nucleotide analogues are currently in clinical development for the treatment of chronic hepatitis B. However, the efficacy of newer agents against lamivudine-resistant hepatitis B virus (HBV) has not been fully explored. To investigate this in vitro, we generated novel stable cell lines expressing HBV encoding the four major patterns of lamivudine resistance mutations (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I and rtL180M+ rtM204I). Using these cell lines, we assessed the susceptibility of all four strains of lamivudine-resistant HBV to eleven nucleoside analogues in various stages of clinical development. Our studies indicate that lamivudine-resistant HBV remain sensitive to acyclic phosphonate nucleotides (adefovir, tenofovir, and alamifovir), have reduced susceptibility to entecavir, and have high-level cross-resistance to all L-nucleosides tested including emtricitabine, telbivudine, clevudine, and torcitabine.
References
1.
LiawY.F., ChienR.N., & YehC.T.No benefit to continue lamivudine therapy after emergence of YMDD mutations.Antiviral Therapy2004; 9: 257–262.
2.
LocarniniS., HatzakisA., HeathcoteJ., KeeffeE.B., LiangT.J., MutimerD., PawlotskyJ.M., & ZoulimF.Management of antiviral resistance in patients with chronic hepatitis B.Antiviral Therapy2004; 9: 679–693.
3.
LaiC.L., DienstagJ., SchiffE., LeungN.W., AtkinsM., HuntC., BrownN., WoessnerM., BoehmeR., & CondreayL.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.Clinical Infectious Diseases2003; 36: 687–696.
4.
AllenM.I., DeslauriersM., AndrewsC.W., TipplesG.A., WaltersK.A., TyrrellD.L., BrownN., & CondreayL.D.Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.Hepatology1998; 27: 1670–1677.
5.
MelegariM., ScaglioniP.P., & WandsJ.R.Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.Hepatology1998; 27: 628–633.
6.
OnoS.K., KatoN., ShiratoriY., KatoJ., GotoT., SchinaziR.F., CarrilhoF.J., & OmataM.The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.Journal of Clinical Investigation2001; 107: 449–455.
7.
DelaneyW.E., YangH., WestlandC.E., DasK., ArnoldE., GibbsC.S., MillerM.D., & XiongS.The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.Journal of Virology2003; 77: 11833–11841.
8.
WestlandC.E., YangH., DelaneyW.E.IV, NaminiH., LamaN., GibbsC.S., MillerM.D., FryJ., BrosgartC.L., SchiffE.R., & XiongS.Activity of adefovir dipivoxil against all major patterns of lamivudine-resistant HBV in patients.Journal of Viral Hepatitis2005; 12: 67–73.
9.
AngusP., VaughanR., XiongS., YangH., DelaneyW., GibbsC., BrosgartC., ColledgeD., EdwardsR., AyresA., BartholomeuszA., & LocarniniS.Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.Gastroenterology2003; 125: 292–297.
10.
YangH., WestlandC.E., DelaneyW.E.IV, AngusP., KitisG., LocarniniS., BrosgartC.L., WulfsohnM., GibbsC.S., MillerM.D., & XiongS.Resistance monitoring in chronic hepatitis B patients following 96 weeks of adefovir dipivoxil therapy.Hepatology2004; in press.
11.
YangH., QiX., DasK., ArnoldE., WestlandC., DelaneyI.V. W., BrosgartC., GibbsC., MillerM., & XiongS.In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase.Journal of Hepatology2004; 40: 114.
12.
QiX., SnowA., ThibaultV., ZhuY., CurtisM., HadziyannisS., BrosgartC., CurrieG., ArterburnS., GibbsC., MillerM., & XiongS.Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy.Journal of Hepatology2004; 40: 20–21.
13.
LokA.S.New treatment of chronic hepatitis B.Seminars in Liver Disease2004; 24 (Suppl 1): 77–82.
14.
ChinR., ShawT., TorresiJ., SozziV., TrautweinC., BockT., MannsM., IsomH., FurmanP., & LocarniniS.In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl- beta-l-arabinofuranosyluracil.Antimicrobial Agents & Chemotherapy2001; 45: 2495–2501.
15.
SeigneresB., PichoudC., MartinP., FurmanP., TrepoC., & ZoulimF.Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.Hepatology2002; 36: 710–722.
16.
RistigM.B., CrippinJ., AbergJ.A., PowderlyW.G., Lisker-MelmanM., KesselsL., & TebasP.Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.Journal of Infectious Diseases2002; 186: 1844–1847.
17.
NunezM., Perez-OlmedaM., DiazB., RiosP., Gonzalez-LahozJ., & SorianoV.Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.AIDS2002; 16: 2352–2354.
18.
van BommelF., WunscheT., SchurmannD., & BergT.Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.Hepatology2002; 36: 507–508.
19.
YeniP.G., HammerS.M., HirschM.S., SaagM.S., SchechterM., CarpenterC.C., FischlM.A., GatellJ.M., GazzardB.G., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SchooleyR.T., ThompsonM.A., VellaS., & VolberdingP.A.Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.Journal of the American Medical Association2004; 292: 251–265.
20.
GuntherS., LiB.C., MiskaS., KrugerD.H., MeiselH., & WillH.A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients.Journal of Virology1995; 69: 5437–5444.
21.
WeinbergerK.M., WiedenmannE., BohmS., & JilgW.Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR).Journal of Virological Methods2000; 85: 75–82.
22.
YangH., WestlandC.E., DelaneyW.E.IV, HeathcoteE.J., HoV., FryJ., BrosgartC., GibbsC.S., MillerM.D., & XiongS.Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks.Hepatology2002; 36: 464–473.
23.
YingC., De ClercqE., NicholsonW., FurmanP., & NeytsJ.Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, l-FMAU, DAPD, penciclovir and lobucavir [In Process Citation].Journal of Viral Hepatitis2000; 7: 161–165.
24.
TenneyD.J., LevineS.M., RoseR.E., WalshA.W., WeinheimerS.P., DiscottoL., PlymM., PokornowskiK., YuC.F., AngusP., AyresA., BartholomeuszA., SievertW., ThompsonG., WarnerN., LocarniniS., & ColonnoR.J.Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.Antimicrobial Agents & Chemotherapy2004; 48: 3498–3507.
DasK., XiongX., YangH., WestlandC.E., GibbsC.S., SarafianosS.G., & ArnoldE.Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).Journal of Virology2001; 75: 4771–4779.
27.
YuenM.F., KimJ., AverettD., WongD.K.H., KimC.R., KerrB., NgaiV.W.S., YuenY.C.H., & LaiC.L.Phase I/II double-blind, randomized, placebo-controlled study of the novel antivi-HBV agent LB803038/ANA038 in patients with chroinc HBV infection.Hepatology2004; 40: 172A.
28.
DelaneyW.E.IV, WestlandC.E., YangH.L., LinK.Y., DasK., ArnoldE., JainA.K., MillerM.D., GibbsC.S., & XiongX.Cross-resistance analysis of lamivudine, adefovir, and entecavir using a cell culture model of HBV replication.Antiviral Research2001; 50: A81.
29.
YaoG., ZhouX., XuD., WangB., RenH., JiangM., LiuJ.D., XuD., & MacDonaldL.A randomized, placebo-controlled study (ETV-056) in China of the efficacy and safety of entecavir in chronic hepatitis B patients who have failed lamivudine.Hepatology2004; 40: 647A.
30.
ShermanM., YurdaydinC., SollanoJ., SilvaM., GoodmanZ., ChenL., CrossA., DehertoghD., & HindesR.Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026.Hepatology2004; 40: 664A.
31.
ChangT.T., GishR., De ManR., GadanoA., SollanoJ., HanK.H., GoodmanZ., ZhuJ., CrossA., DehertoghD., & ApelianD.Entecavir is superior to lamivudine for the treatment of Hbeag(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naïve patients.Hepatology2004; 40: 193A.
32.
PetersM.G., Hann HwH., MartinP., HeathcoteE.J., BuggischP., RubinR., BourliereM., KowdleyK., TrepoC., Gray DfD., SullivanM., KleberK., EbrahimiR., XiongS., & BrosgartC.L.Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.Gastroenterology2004; 126: 91–101.
33.
TillmannH.L., TrautweinC., BockT., BokerK.H., JackelE., GlowienkaM., OldhaferK., BrunsI., GauthierJ., CondreayL.D., RaabH.R., & MannsM.P.Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation.Hepatology1999; 30: 244–256.
34.
SeigneresB., PichoudC., AhmedS.S., HantzO., TrepoC., & ZoulimF.Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B [in process citation].Journal of Infectious Diseases2000; 181: 1221–1233.
35.
HanS., LeungN., TeoE.K., TongM., WongF., W.HH, PoynardT, MyersM, ChaoG, LloydD, BrownN, & LaiCL.Results of a one-year international phase IIB trial of LdT and LdT plus lamivudine in patients with chronic hepatitis B.Journal of Hepatology2004; 40: 16.
